Laws · District of Columbia · November 16, 2026
A study in the American Business Law Journal examines cannabis regulatory confusion and how it shapes consumer adoption. Authors Stephanie Geiger-Oneto and Robert Sprague say U.S. rules are inconsistent: marijuana stays Schedule I federally, yet eleven states and D.C. had legalized recreational use and thirty-six states and D.C. allowed medical use by the end of 2020.
Why it matters: The research suggests mixed legal signals do more than confuse; they may keep cannabis a stigmatized product even as legal access grows. For consumers and patients, that means the federal-state conflict can shape how legitimate the products seem, and how comfortable people feel buying them, not just whether purchases are legal.
Read moreSource: ebsco.com
Laws · District of Columbia, Maryland, Virginia · November 15, 2026
IgniteIt's Capital & Policy Summit returns to the Grand Hyatt Washington on Wednesday, November 18, for its second Washington, D.C. edition. Congresswoman Dina Titus is set to discuss what follows rescheduling. Panels cover hemp, Virginia's coming market, capital markets and M&A, with regulators from Virginia, Maryland and D.C. on the bill.
Why it matters: The lineup shows where the industry expects the next fights: life after rescheduling, the hemp loophole as a congressional extension runs out December 11, and new mid-Atlantic markets. For consumers and patients, those debates shape future product availability, hemp-derived product rules and how regional markets take form. Nothing is decided at the event itself.
Read moreSource: Ganjapreneur
Laws · District of Columbia, New Mexico · November 15, 2026
The Senate Appropriations Committee wants to keep the federal medical marijuana rider that shields state programs from Justice Department interference. Its Fiscal Year 2027 spending bill leaves out the House's ban on funding rescheduling. The committee also wants briefings on cannabis seizures from state-legal businesses and a report on illegal grows tied to foreign nationals.
Why it matters: Patients in state programs would keep the funding shield that has restrained federal prosecutors since 2014, so the Senate draft signals no change there. Dropping the House's rescheduling block leaves the administration's Schedule III effort unobstructed by this bill. Nothing is final, though: no votes are scheduled, and the House and Senate versions differ.
Read moreSource: Marijuana Moment
Laws · District of Columbia · November 12, 2026
The DEA has sent orders rejecting medical cannabis businesses that sought federal registration and protections under rescheduling, according to Marijuana Moment. The rejections cover at least six states and Washington, D.C., and the agency raised various objections to those jurisdictions' marijuana laws. The DEA rejects cannabis registrations at a moment when the Trump administration is moving to reschedule marijuana.
Why it matters: Rescheduling was expected to give licensed medical cannabis businesses a path to federal registration and its protections. Rejections in several jurisdictions suggest that path may depend on how closely local rules match federal objections. For patients, that raises uncertainty about whether the supply chains serving their state or district programs will gain federal standing soon.
Read moreSource: Marijuana Moment